SCOPUS 정보 검색 플랫폼

Volumn 38, Issue 4 SUPPL., 2005, Pages 175-179

Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: A paradigm for the critical pathway initiative

(3) Cabell, Christopher H a,b Noto, Tory C b Krucoff, Mitchell W a,b

a DUKE UNIVERSITY SCHOOL OF MEDICINE (United States)

b DUKE CLINICAL RESEARCH INSTITUTE (United States)

Author keywords

Critical Path Initiative; Electrocardiogram Warehouse; Food and Drug Administration

Indexed keywords

ASTEMIZOLE; CISAPRIDE; CYCLOOXYGENASE 2 INHIBITOR; GREPAFLOXACIN; ROFECOXIB; SERTINDOLE; TERFENADINE;

BIOMEDICINE; CAUSE OF DEATH; CHRONIC DISEASE; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG SAFETY; ELECTROCARDIOGRAM; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HUMAN; INDUSTRY; INVESTMENT; MEDICAL RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; STANDARD; TACHYCARDIA; TORSADE DES POINTES;

CRITICAL PATHWAYS; DRUG APPROVAL; DRUG TOXICITY; ELECTROCARDIOGRAPHY; HUMANS; LEGISLATION, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 26444467079 PISSN: 00220736 EISSN: None Source Type: Journal
DOI: 10.1016/j.jelectrocard.2005.06.104 Document Type: Conference Paper

Times cited : (7)

References (8)

1
- 26444532063
- Seldane and generic terfenadine withdrawn from market
- February 27
- Kupec I. Seldane and generic terfenadine withdrawn from market. FDA Talk Paper. February 27, 1998. Accessed June 9, 2005, at www.fda.gov/bbs/topics/ ANSWERS/ANS00853.html.
- (1998) FDA Talk Paper
- Kupec, I.¹

2
- 26444547771
- House of Representatives, and Committee on Energy and Commerce, Subcommittee on Health Hearings on reauthorization of the Prescription Drug User Fee Act. (Serial number 107-93.) March, 6, 2002 Accessed June 9, 2005, at http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname= 107_house_hearings&docid=f:78503.pdf
- Hearings on Reauthorization of the Prescription Drug User Fee Act. (Serial Number 107-93.) March, 6, 2002
- Of Representatives, H.¹ On Energy, C.² Commerce³ On Health, S.⁴

3
- 26444459555
- D. Graham FDA, Merck and Vioxx: Putting Patient Safety First? Hearings, United States Senate Committee on Finance. November 18 2004
- (2004) FDA, Merck and Vioxx: Putting Patient Safety First? Hearings, United States Senate Committee on Finance. November 18
- Graham, D.¹

4
- 26444567944
- US Senate Press Release. April 27
- US Senate Press Release. Grassley, Dodd expand effort to improve drug safety system. April 27, 2005.
- (2005) Grassley, Dodd Expand Effort to Improve Drug Safety System

5
- 14944360098
- What ails the FDA?
- S. Okie What ails the FDA? N Engl J Med 352 2005 1063
- (2005) N Engl J Med , vol.352 , pp. 1063
- Okie, S.¹

6
- 0034279025
- User fees for faster drug review: Are they helping or hurting the public health?
- L. Thompson User fees for faster drug review: are they helping or hurting the public health? FDA Consum Mag 2000
- (2000) FDA Consum Mag
- Thompson, L.¹

7
- 26444577956
- Department of Health and Human Services, Office of Inspector General FDA's review process for new drug applications: a management review (OEI-01-01-00590). March 2003 Accessed June 9, 2005, at http://www.oig.hhs.gov/ oei/reports/oei-01-01-00590.pdf
- FDA's Review Process for New Drug Applications: A Management Review (OEI-01-01-00590). March 2003
- Of Health, D.¹ Services, H.² Of Inspector General, O.³

8
- 74549144459
- J. Woodcock FDA's "Critical Path" Initiative. June 7, 2004 Accessed June 9, 2005, at http://www.fda.gov/oc/initiatives/criticalpath/ woodcock/woodcock.html
- FDA's "critical Path" Initiative. June 7, 2004
- Woodcock, J.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.